In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
News|Articles|December 19, 2014
EMA Recommends Seven New Medicines for Marketing Authorization
Author(s)Pharmaceutical Technology Editors
The Committee for Medicinal Products for Human Use recommended seven new medicines at a December 2014 meeting, including weight management and Parkinson’s disease treatments.
Advertisement
At the European Medicine’s Agency Committee for Medicinal Products for Human Use (CHMP) meeting, held Dec. 15–18, 2014, it was announced that seven new medicines would be recommended for marketing authorization in Europe, bringing the total of CHMP-recommended medicines in 2014 to 82:
- Holoclar-An orphan medicine that is the first advanced therapy containing stem cells recommended for approval in the EU,
Holoclar is used in the treatment of moderate to severe limbal stem-cell deficiency due to physical or chemical burns to the eyes in adults.
- Mysimba (naltrexone/bupropion)-Used for weight management in obese adults, or those that are experiencing complications due to their weight.
- Xadago (safinamide)-Used in the treatment of Parkinson’s disease.
- Xydalba (dalbavancin)-Used in the treatment of skin and skin structure infections.
- Quinsair (levofloxacin)-Used in the treatment of chronic pulmonary infections due to
Pseudomonas aeruginosa in adults with cystic fibrosis.
- Tasermity (sevelamer hydrochloride)-Used in the treatment of hyperphosphataemia in adults receiving dialysis.
- Clopidogrel ratiopharm (clopidogrel)-Used for the prevention of myocardial infarction, ischaemic stroke, peripheral arterial disease, acute coronary syndrome, and in the prevention of atherothrombotic and thromboembolic events in atrial fibrillation.
In addition to the seven marketing recommendations, there were four medicines recommended for extensions of indication: Revlimid, Tresiba, Velcade, and Xiapex.
Source:
Advertisement
Related to this article
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
Karthik Iyer, Eli Lilly, detailed an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
2
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
3
PharmTech AI Pulse Check: Fixing AI Slop at the Source
4
Pharma Fundamentals: Digital Pathology in Drug Development, Part 1
5